AUTHORS
Armin Ghobadi, MD, Joseph P McGuirk, DO2, Constantine S. Tam, MD,MBBS3, Narendranath Epperla, MD, MS, FACP4, Paul Shaughnessy, MD5, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA6, Ziliang Li, PhD7, Shilpa Murthy, MD, MBA8, Naimish Patel, MD9, John T. O'Malley, MD, PhD10, Leah Williams, PhD11, Melanie R. Allen, MS12, Chan Cheah, MBBS, DMSc13
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 University of Kansas Medical Center, Kansas city, Kansas, United States
3 Alfred Hospital and Monash University, Melbourne, Victoria, Australia
4 Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States
5 Methodist Hospital, San Antonio, Texas, United States
6 Royal Prince Alfred Hospital, University of Sydney, Camperdown, New South Wales, Australia
7 CRISPR Therapeutics, Boston, Massachusetts, United States
8 CRISPR Therapeutics, Boston, Massachusetts, United States
9 CRISPR Therapeutics, Boston, Massachusetts, United States
10 CRISPR Therapeutics, Boston, Massachusetts, United States
11 CRISPR Therapeutics, Boston, Massachusetts, United States
12 CRISPR Therapeutics, Boston, Massachusetts, United States
13 Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
ABSTRACT
Introduction: Zugocabtagene geleucel (zugo-cel, formerly CTX112) is an off-the-shelf, allogeneic CD19 CAR T cell utilizing CRISPR-Cas9 editing of healthy donor T cells with 5 edits, including site-specific insertion of an anti-CD19 CAR transgene into the TCR alpha constant (TRAC) locus via adeno-associated viral delivery, and targeted disruption of 4 genes: TRAC (to prevent graft-versus-host disease), B2M (to remove MHC class I expression), TGFBR2 (to overcome immunosuppressive tumor microenvironment signaling), and ZC3H12A (Regnase-1, to promote CAR T functional persistence). NCT05643742 is a phase 1/2, open-label, multicenter study evaluating the safety and efficacy of CTX112 in subjects with relapsed or refractory (r/r) B-cell malignancies. In previously reported data from 12 patients (pts), zugo-cel demonstrated high response rates across non-Hodgkin lymphoma (NHL) subtypes (Ghobadi et al, ASH 2024). Here we present updated data focused on pts with relapsed/refractory large B cell lymphoma (LBCL) from the CRSP-ONC-006 study as of a June 8, 2026, data cutoff.
Methods: Pts received lymphodepleting chemotherapy (fludarabine 30 mg/m2, cyclophosphamide 500 mg/m2 for 3 days) followed by zugo-cel infusion. The primary endpoint was incidence of dose-limiting toxicities (DLTs); secondary endpoints included ORR/CR rates per Lugano 2014 criteria and pharmacokinetics (PK).
Results: A total of 26 LBCL pts were treated across 4 dose levels (DL1, n=2: 3x107, DL2, n=1: 1x108, DL3, n=6: 3x108 and DL4, n=17: 6x108 CAR+ T cells). This high-risk pt population was enriched for adverse prognosis features: 54% (14/26) with primary refractory disease, 54% (14/26) with early relapse within 12 months (mo) of primary therapy, median SPD 2397mm2 (range 105-10492), 58% (15/26) elevated LDH, 50% (13/26) IPI >3, and 69% (18/26) aged >65. Median age was 68 (range 45-81) and median prior lines of therapy was 3 (range 1-10), including 6 pts with prior CD3-directed bispecific antibodies (BsAbs) and 2 with prior CD19-directed autologous CAR T therapy.
Serious adverse events (SAEs) were reported in 77% (20/26) of all LBCL pts with CRS (54%, 14/26) and ICANS (42%, 11/26) being the most common. Across all LBCL pts, any-grade CRS and ICANS occurred in 81% (21/26) and 46% (12/26) of pts, respectively. At DL4, Grade 3 CRS and Grade 3 ICANS each occurred in 17.6% (3/17) of pts, and Grade ≥3 infections occurred in 11.8% (2/17) of pts. Two DLT events of Grade 3 ICANS were reported at DL4, both resolved with standard of care treatment. Ten (10/26) deaths occurred among LBCL pts, none considered treatment-related. Zugo-cel’s safety profile was acceptable across dose levels and comparable to autologous anti-CD19 CAR T therapies.
PK analysis from peripheral blood showed mean peak zugo-cel expansion (Cmax) occurred around Day 8 post-infusion. DL3 (n=6, 104,262 copies/µg) and DL4 (n=17, 86,582 copies/µg) had comparable Cmax values, both substantially greater than DL1 and DL2 combined (n=3, 248 copies/µg).
Among 24 LBCL pts across all dose levels who reached Day 28 visit, ORR was 75% (18/24) and CR rate was 50% (12/24), with DL4 achieving 63% (10/16) CR rate. With a median follow-up of 6.8 mo (range 2.0-21.0), among DL4 pts who achieved D28 CR, 70% (7/10) maintained their response with 2 pts in ongoing CR at mo 18 visit as of the data cutoff. A distinct difference in PK exposure was also observed between responders and non-responders: median Cmax at DL4 was ~27-fold higher for responders vs. non-responders at Month 3 (166,605 vs. 6,159 copies/µg), demonstrating a strong exposure-response relationship.
Conclusions: The correlation between cell dose, response, PK, and toxicity demonstrates an exposure-response relationship for zugo-cel in a highly refractory LBCL population that had exhausted multiple prior therapies, including BsAbs and autologous CAR T. Based on this favorable benefit-risk profile, DL4 was chosen as the recommended phase 2 dose (RP2D). As a readily available, off-the-shelf allogeneic therapy, zugo-cel offers the potential to rapidly treat patients who have failed multiple prior therapies, including those who are transplant-ineligible. Its novel CRISPR-Cas9 edits position zugo-cel as a promising monotherapy and a potential partner for combination therapy with pirtobrutinib to further deepen and prolong responses in this challenging population.
DISCLOSURES
Armin Ghobadi, MD: Novartis - Honoraria; BMS - Honoraria; Wugen/Allotera - Honoraria; Amgen - Honoraria; CRISPR Therapeutics AG - Honoraria; Kite - Honoraria; Atara - Honoraria; Genentech - Research Funding; Secura Bio - Research Funding; Novartis - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); CRISPR Therapeutics AG - Consultancy (Includes expert testimony); Atara - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Wugen/Allotera - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)